Combined oral ivermectin and 5% permethrin cream to treat severe scabies (Registro nro. 22926)

000 -Cabecera
Campo de control interno 02813nam a2200301 4500
001 - Número de control
control field ESSALUD
005 - Fecha y hora de la última transacción
Campo de control 20260903142646.0
007 - Tipo material - Descripcion fisica - info general
Tipo material - Descripcion fisica - info general ta
008 - Elementos de Longitud Fija - Información General
Elementos de Longitud Fija - Información t pe ||||| |||| 00| 0 spa d
040 ## - Origen de la Catalogación
Origen de la Catalogación BMG
041 ## - Idioma
Idioma eng
100 ## - Autor
Autor Bernigaud, Charlotte
Rol del Autor Autor
9 (RLIN) 54546
245 ## - Titulo
Titulo Combined oral ivermectin and 5% permethrin cream to treat severe scabies
300 ## - Páginas
Paginación páginas: 1814-1823
520 ## - Resumen
Resumen Background: Severe scabies, a rare parasitic skin disease characterized by abundant skin mites, may be life-threatening and poses public health concerns worldwide. A combination of standard-dose oral ivermectin and topical scabicides is recommended for treatment. However, data from randomized clinical trials are lacking, and the probability of cure is uncertain. Ivermectin at higher doses has been effective in the treatment of some parasitic diseases. Methods: We conducted a blinded randomized trial involving adults with severe scabies (i.e., profuse or crusted), as confirmed by parasitologic or dermoscopic assessment. The patients were assigned in a 1:1 ratio to receive oral ivermectin (to be taken with food) at a dose of 400 μg per kilogram of body weight (higher-dose group) or 200 μg per kilogram (standard-dose group) on days 0, 7, and 14, combined with head-to-toe application of 5% permethrin cream on days 0 and 7 and daily application (as recommended) of an emollient cream. The primary end point was cure of severe scabies, which was defined as the absence of mites and mite-related products (i.e., eggs and feces), as confirmed by parasitologic or dermoscopic assessment on days 18 and 21, and the absence of active clinical lesions on physical examination on day 28. Results: A total of 132 patients (66 in each group) were included in the main analysis. Cure was observed in 75% of the patients in the higher-dose group and in 82% of those in the standard-dose group (odds ratio for cure, 0.64; 95% confidence interval, 0.25 to 1.67). No safety issues were identified. Conclusions: Among adults, the 400-μg-per-kilogram dose of ivermectin plus 5% permethrin cream was not superior to the standard 200-μg-per-kilogram dose of ivermectin plus 5% permethrin cream in curing severe scabies.
650 ## - Temas - Descriptores
Temas - Descriptores DERMATOLOGÍA GENERAL
9 (RLIN) 54449
650 ## - Temas - Descriptores
Temas - Descriptores SALUD GLOBAL
9 (RLIN) 10472
650 ## - Temas - Descriptores
Temas - Descriptores ENFERMEDADES INFECCIOSAS GENERALES
9 (RLIN) 54087
650 ## - Temas - Descriptores
Temas - Descriptores INFECCIONES PARASITARIAS
9 (RLIN) 54373
700 ## - Autor Personal
Autor Personal Do-Pham, Giao
9 (RLIN) 54547
700 ## - Autor Personal
Autor Personal Guichard, Elie
9 (RLIN) 54548
700 ## - Autor Personal
Autor Personal Beylot-Barry, Marie
9 (RLIN) 54549
700 ## - Autor Personal
Autor Personal Goujon, Elisa
9 (RLIN) 54550
700 ## - Autor Personal
Autor Personal Isnard, Camille
9 (RLIN) 54551
700 ## - Autor Personal
Autor Personal Beneton, Nathalie
9 (RLIN) 54552
773 0# - Revista (Relacion con el numero)
Host Biblionumber 22717
Host Itemnumber 22676
Ciudad, Editorial Massachusetts NEJM Group
Codigo barras item/ejemplar NEJM015
Titulo de la Revista The New England Journal of Medicine
Número de control de registro ESSALUD
ISSN 0028-4793
942 ## - Elementos de Koha
Tipo de Documento Artículos
Fecha procesamiento 2026-08-31
Catalogador sqb

No hay ítems disponibles.